|
Original publications |
| 1. |
224 Quotations |
|
Kielstein JT, Böger RH, Bode-Böger SM,
Schäffer J, Barbey M, Koch KM, Frölich JC. Asymmetric dimethylarginine
plasma concentrations differ in patients with end-stage renal disease: relationship
to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;
10: 594-600.
|
| 2. |
155 Quotations |
|
Kielstein JT, Böger RH, Bode-Böger SM,
Frölich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric
dimethylarginine in patients with incipient primary chronic renal disease.
J Am Soc Nephrol 2002; 13: 170-176.
|
| 3. |
154 Quotations |
|
Kielstein JT, Impraim B, Simmel S, Bode-Böger SM,
Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects
of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine
in humans. Circulation 2004; 109: 172-177.
|
| 4. |
87 Quotations |
|
Kielstein JT, Bode-Böger SM, Frölich JC, Ritz
E, Haller H, Fliser D. Asymmetric dimethylarginine (ADMA), blood pressure and
renal perfusion in elderly subjects. Circulation 2003; 107: 1891-1895.
|
| 5. |
60 Quotations |
|
Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ,
Haller H, Fliser D. Efficacy and cardiovascular tolerability of extended dialysis
in critically ill patients: a randomized controlled study.
Am J Kidney Dis 2004; 43: 342-349.
|
| 6. |
46 Quotations |
|
Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A,
Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM.
ADMA increases arterial stiffness and decreases cerebral blood flow in human.
Stroke 2006; 37(8):2024-9
|
|
Reviews |
| 1. |
63 Quotations |
|
Kielstein JT, Zoccali C. Asymmetyric Dimethylarginine:
A cardiovascular risk factor and a uremic toxin coming of age?
Am J Kidney Dis 2005; 46: 186-202.
|